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Abstract
Background: Lipoprotein profiles in HIV-infected African women have not been well described. We assessed
associations of lipoprotein levels and cardiovascular risk with HIV-infection and CD4 count in Rwandan women.
Methods: Cross-sectional study of 824 (218 HIV-negative, 606 HIV+) Rwandan women. Body composition by body
impedance analysis, CD4 count, and fasting serum total cholesterol (total-C), triglycerides (TG) and high-density
lipoprotein (HDL) levels were measured. Low-density lipoprotein (LDL) was calculated from Friedewald equation if
TG < 400 and measured directly if TG ≥ 400 mg/dl.
Results: BMI was similar in HIV+ and -negative women, < 1% were diabetic, and HIV+ women were younger. In
multivariate models LDL was not associated with HIV-serostatus. HDL was lower in HIV+ women (44 vs. 54 mg/dL,
p < 0.0001) with no significant difference by CD4 count (p = 0.13). HIV serostatus (p = 0.005) and among HIV+
women lower CD4 count (p = 0.04) were associated with higher TG. BMI was independently associated with
higher LDL (p = 0.01), and higher total body fat was strongly associated with higher total-C and LDL. Framingham
risk scores were < 2% in both groups.
Conclusions: In this cohort of non-obese African women HDL and TG, but not LDL, were adversely associated
with HIV infection. As HDL is a strong predictor of cardiovascular (CV) events in women, this HIV-associated
difference may confer increased risk for CV disease in HIV-infected women.
Introduction
Dyslipidemias have been described since 1989 in indivi-
duals with human immunodeficiency virus (HIV) infec-
tion in resource-replete countries, prior to the
availability of combination antiretroviral therapy
(cART), in studies primarily of white men [1-6]. Quanti-
tative abnormalities include higher triglyceride levels
(TG) [2-6] and lower levels of total cholesterol (total-C)
[1,5-7], high-density lipoprotein (HDL) [3,6,8] and low-
density lipoprotein (LDL) [1-7,9] cholesterol. These
abnormalities are greater with more advanced immune
suppression [2-6]. Patterns of lipoprotein changes are
somewhat different in HIV-infected women [10], with
most studies showing no association of HIV-infection
with lower LDL. Both women and African Americans in
general have higher HDL and lower TG than do
European American men [11,12]. Further information is
required regarding lipoprotein profiles and potential car-
diovascular risk in HIV-infected Africans, who start with
lower total-C, TG and LDL, and higher HDL, compared
to individuals of European descent living in resource-
replete settings. A South African study found lower
HDL and LDL and higher TG in HIV-infected com-
pared to uninfected patients [13], and a study in Uganda
has reported little change in lipoprotein levels over a
two-year period in patients initiating cART [14].
In sub-Saharan Africa and the United States, women
and/or people of African descent represent the majority
of those infected with and treated for HIV-infection.
Because cardiovascular disease (CVD) is a growing con-
cern for HIV infected individuals [15,16] and in develop-
ing countries, and dyslipidemia is a major risk factor for
CVD, we assessed cardiovascular risk and predictors of
lipoprotein levels in HIV-infected and uninfected Rwan-
dan women. * Correspondence: kanastos@verizon.net
1Montefiore Medical Center, Bronx NY, USA
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Study Population
The Rwanda Women’s Interassociation Study and
Assessment (RWISA) is an observational prospective
cohort study of HIV-infected and uninfected Rwandan
women investigating the effectiveness and toxicity of
antiretroviral therapy. In 2005, 710 HIV-infected and
226 HIV-uninfected women were enrolled with follow-
up visits occurring every six months. Informed consent
was obtained in accordance with protocols approved by
the Rwandan National Ethics Committee and the Insti-
tutional Review Board of Montefiore Medical Center,
Bronx NY, USA. Participants were recruited through
grassroots women’s organizations and clinical care sites
for HIV-infected patients. Inclusion criteria were: age 25
years or older at study entry, willingness to give
informed consent, presence in Rwanda during 1994 and
no history of receiving antiretroviral treatment except
single dose nevirapine to prevent mother-to-child trans-
mission of HIV. At study entry participants provided
historical information including socio-demographics,
medical and psychosocial history and symptoms, and
experience of trauma during the 1994 Rwandan geno-
cide. A physical examination and body impedance analy-
sis (BIA) were performed, and fasting blood specimens
were taken. This cross-sectional analysis includes enroll-
ment data from 824 participants for whom fasting lipo-
protein levels were measured at study enrollment.
Laboratory Methods
Total-C, triglyceride and HDL analysis and albumin
determination (as a proxy biochemical measure of nutri-
tional status), were performed in the laboratory of King
Faisal Hospital in Kigali, Rwanda using standard labora-
tory methods. For 112 women lipid values were not
available because of a lack of reagents at the time of
their study visits. LDL was calculated with the Friede-
wald equation [17], using measured values for total cho-
lesterol, HDL and triglycerides. [LDL = (total-C) -
(HDL) - (Trig/5.0)]. If triglyceride level was ≥ 400 mg/
dL (n = 11), LDL was measured directly by Quest
Laboratory in Baltimore Maryland USA. CD4 counts
were determined with a FACS counter (Becton and
Dickinson, Immunocytometry Systems, San Jose, CA,
USA) at the National Reference Laboratory of Rwanda.
Exposure variables
The primary exposure variables were HIV serostatus
(positive vs. negative) and in the HIV-positive women
CD4 cell count, both as a continuous variable (per 100
cells/μl increment) and categorized as < 200, 200-350,
and > 350 cells/μl. Secondary exposure variables
included age, income, educational attainment, body
mass index (BMI) calculated as weight in kilograms
divided by (height in meters)
2, total body fat (TBF) and
lean body mass calculated from BIA body composition
measures and weight, self-reported menopausal status,
current tobacco smoking (yes vs. no), history of diabetes
mellitus defined by self-report or fasting plasma glucose
> 125 mg/dL, and a reported perception of having ade-
quate food. HIV-1 RNA was included for the 271 HIV+
women whose value was measured.
Outcome Variables
The primary outcomes of interest were total-C, LDL,
HDL, and TG, and calculated Framingham 10-year CVD
risk.
Statistical Methods
Analysis of variance or chi-square tests were used to
compare mean lipid levels and percent of participants
with abnormal lipid levels among groups defined by
HIV status and CD4 count. Variables included in the
multivariate models were chosen by their association
with lipoprotein values in univariate analysis; variables
with p < 0.10 were included in the multivariable models
analyzing the outcome variables among the groups. If
the overall ANOVA test for differences in lipid levels
among > 2 groups was significant, two-sample tests
were used to assess pair-wise comparisons. Otherwise,
pair-wise comparisons are not reported. In assessment
of the Framingham Risk Score (FRS) we performed an
age-matched analysis, with each pair randomly selected
with the age-difference within +/- 2 years. We also cal-
culated FRS without including the age component. All
analyses were performed using the SAS statistical pack-
age (Version 8, SAS Institute, Cary, NC).
Results
Demographic and clinical characteristics of the 606 HIV
+ and 218 HIV-negative participants included in this
analysis are shown in Table 1. The HIV+ women were
younger and were less likely to be post-menopausal.
Less than 4% of women in either group used tobacco or
illicit drugs, and 0.5% were diabetic.
Associations with HIV serostatus and CD4 cell count
Unadjusted and adjusted mean lipoprotein values are
shown in Tables 1 and 2 respectively. In both adjusted
and unadjusted analyses, mean LDL and non-HDL were
similar in the HIV-positive and negative women and did
not vary by CD4 count in the HIV+ participants. In
adjusted models (Table 2), total-C (p = 0.014) and HDL
(p < 0.0001) were lower in HIV+ than in HIV-negative
participants without significant variation by CD4 count.
The differences in total-C were driven predominately by
Anastos et al. AIDS Research and Therapy 2010, 7:34
http://www.aidsrestherapy.com/content/7/1/34
Page 2 of 6Table 1 Participant Characteristics, Unadjusted Lipoprotein Levels, by HIV Serostatus and CD4 Count
HIV negative
N = 218
HIV+ women (all)
N = 606
P-value HIV+ CD4 > 350
n = 158
HIV+ CD4 200-350
n = 224
HIV+ CD4
< 200
n = 222
P-value
Age (years) Mean (SD) 42.4 (10.5) 34.7 (6.8) < 0.0001 34.0 (6.8) 34.9 (6.5) 34.9 (7.2) 0.35
Body Mass Index (Kg/m
2)
Median (IQR) 20.6 (18.6,23.5) 21.1
(19.1, 23.4)
0.40 21.7 (19.0,23.8) 21.3 (19.2,24.0) 20.9 (19.0,23.1) 0.068
Total Body Fat (Kg)
Median (IQR) 11.4
(6.6, 19.0)
12.0
(7.9, 17.0)
0.95 11.4
(7.9, 16.5)
12.1
(7.75, 17.5)
12.1
(7.9, 16.4)
0.43
Lean Body Mass (Kg)
Median (IQR) 41.8
(38.7, 44.9)
40.0
(37.2, 43.0)
0.0006 40.5
(38.4, 43.5)
40.4
(37.5, 44.2)
39.3
(35.9, 42.0)
0.013
Post-menopausal (%) 22.2 5.7 < 0.0001 6.6 4.9 5.9 0.79
# Sexual partners
1
Mean (SD) 3.6 (5.4) 7.5 (22.7) 0.015 6.3 (15.0) 7.5 (23.9) 8.5(26.0) 0.66
Median (IQR) 2 (1, 4) 3 (2, 6) 3 (2, 5) 3 (2, 5) 3 (2, 6)
Smoking (%) 3.4 2.5 0.50 2.6 2.7 2.3 0.96
Alcohol 0.40 0.73
None 77.1 81.0 83.5 80.4 79.3
1-3 drinks/day 22.5 18.3 16.5 18.8 19.4
> 3 drinks/day 0.5 0.7 0.0 0.9 0.9
Illicit drug use (%) 3.5 2.7 0.57 1.9 2.7 3.2 0.74
Food adequacy (%) 0.41 0.67
Always 0.5 1.6 2.0 0.9 2.1
Most of the time 6.7 5.4 6.8 4.2 5.6
Some of the time 48.3 43.2 41.9 48.1 39.2
Usually not 32.3 37.5 35.1 36.1 40.2
Never 12.1 12.3 14.2 10.7 12.9
Running water in home (%) 4.1 4.8 0.70 5.9 4.5 4.3 0.76
Education (%) 0.0002
No schooling 36.2 23.3 24.7 21.0 24.8 0.32
Grade 1-6 52.8 67.0 68.4 70.1 62.6
Grade 7-11 7.8 8.4 7.0 7.1 10.8
Completed high school 2.3 1.3 0.0 1.8 1.8
Some college 0.9 0.0 0.0 0.0 0.0
Monthly Income $US
Mean (SD)
38 (37.0) 38 (30.3) 0.98 38 (30.2) 37 (30.3) 39 (30.4) 0.89
Diabetes Mellitus (%) 0.5 0.5 0.98 0.7 0.5 0.5 0.96
CD4 cell count (cells/mm
3)
Mean (SD) 878 (299) 275 (163) < 0.0001 487 (137) 274 (43) 124 (51) < 0.0001
HIV-1 RNA* (log10) n = 271 n = 34 n = 93 n = 143
Mean (SD) — 4.06 (1.37) — 3.73 (1.40) 3.94 (1.39) 4.22 (1.35) 0.100
Lipoprotein Levels, mg/dl
Mean (SD)
LDL 71 (29.7) 68 (28.9) 0.20 67 (25.3) 68 (26.) 67 (33.3) 0.98
HDL 54 (16.9) 44 (17.3) < 0.0001 46 (14.5) 45 (19.5) 43 (16.7) 0.13
Non-HDL 89 (33.6) 86 (31.2) 0.21 84 (27.6) 86 (30.7) 87 (34.3) 0.59
Triglycerides 87 (42.0) 94 (47,9) 0.11 82 (32.6) 93(51.6) 102 (50.9) 0.003
Total Cholesterol 143 (36.4) 129 (33.9) < 0.0001 129 (31.5) 130 (32.4) 130 (37.1) 0.92
1 includes rape; *HIV-1 RNA levels available for 271 women; LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein cholesterol, Non-HDL =
Total Cholesterol - HDL.
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analysis TG in the HIV+ women was significantly higher
at lower CD4 counts (p = 0.040), and in HIV+ com-
pared to HIV-negative women (p = 0.005).
Associations of lipid levels with demographic and clinical
variables and measures of nutritional status
In multivariate analyses including HIV serostatus, age,
BMI, menopause, smoking, alcohol use, income, educa-
tion and perception of food availability only BMI was
independently associated with higher LDL (p = 0.01).
Higher HDL was associated with increased alcohol use
(p < 0.001). Age was independently associated with TG
(p = 0.005), and higher non-HDL was associated with
post-menopausal status (p = 0.010), smoking (p = 0.025)
and BMI (p = 0.0001). In additional multivariate analysis
that included albumin, total body fat and lean body
mass, and adjusting for demographic variables, all mea-
sures of nutritional status were strongly associated with
each of the lipoprotein levels. A 1.0 mg/dL higher
serum albumin was associated with large significant
increases in total-C (18 mg/dL), LDL (7 mg/dL) and
HDL (10 mg/dL, p < 0.0001 for all, data not shown).
Higher total body fat (Table 3) was strongly associated
with higher total-C and LDL (p < 0.0001 and = 0.001,
respectively). Similar patterns in the associations of TBF
with lipoprotein levels weres e e ni nt h eH I V - n e g a t i v e
women but were not statistically significant (data not
shown).
Framingham Risk Scores
Framingham 10 year cardiovascular risk (Table 4) was
extremely low in all participants with little variation by
HIV serostatus: 2.04% vs. 1.22% in HIV-negative and
HIV+ women respectively (p < 0.0001). Because of the
older age of the HIV-negative women, we conducted
two additional analyses, and found no significant differ-
ence between HIV-negative and HIV+ women in age-
matched analysis of 154 HIV-negative and 154 HIV+
women (1.57 and 1.63 respectively, p = 0.72) or when
risk scores were calculated without the age component
(1.36 and 1.22, p = 0.15).
Discussion
I nt h i ss t u d yo fH I V - n e g a t i v ea n dA R T - n a ï v eH I V +
Rwandan women we found associations of serum lipo-
protein levels with HIV serostatus and CD4 count that
were similar to those described in United States women
[10]. HDL was markedly lower in the HIV+ women
with some variation by CD4 count, with values very
similar to those in US women, and TG levels were
higher with HIV+ serostatus and advanced immune sup-
p r e s s i o n .A si nU Sw o m e n ,b u tu n l i k eU Sm e n ,L D L
levels did not differ significantly by HIV serostatus or
Table 2 Multivariate associations of Lipoprotein levels with HIV serostatus and CD4 lymphocyte count in 824
participants
Lipoprotein LevelsMean (Standard error) HIV-negative
N = 218
HIV-positive (all)
N = 606
P-value HIV+ CD4 > 350
N = 158
HIV+ CD4
200-350
N = 224
HIV+
CD4 < 200
N = 222
P-value
LDL
1 69 (3.0) 66 (1.7) 0.363 68 (3.2) 65 (2.8) 66 (2.7) 0.74
HDL
2 54 (1.3) 44 (0.8) < 0.0001 46 (1.4) 42 (1.2) 43 (1.3) 0.097
Non-HDL
3 85 (2.5) 87 (1.5) 0.549 85 (2.7) 87 (2.3) 85 (2.4) 0.74
Triglycerides
4 79 (5.0) 96 (2.9) 0.005 82(5.7) 93 (5.0) 101(4.7) 0.040
Total Cholesterol
5 139 (2.8) 130 (1.7) 0.014 131 (3.0) 130 (2.6) 128 (2.7) 0.73
*All models adjusted for age, menopausal status, BMI, income, education, alcohol use, smoking and food availability.
LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein cholesterol, Non-HDL = Total Cholesterol - HDL.
Table 3 Quartiles of total body fat adjusted for CD4 lymphocyte count in HIV-positive women
Lipoprotein Levels
Mean (Standard Deviation)
Total Body Fat in Kilograms P-value
≤ 7.4 7.4 to 11.8 11.8 to 17.4 > 17.4
N 113 135 135 118
LDL 58.5 (28.1) 66.1 (28.2) 66.3 (27.3) 77.7 (30.1) 0.001
HDL 42.7 (16.5) 42.6 (16.6) 43.0 (15.2) 44.7 (12.4) 0.69
Non-HDL 78.5 (29.2) 81.6 (26.9) 87.3 (26.8) 98.8 (36.2) < 0.0001
Triglycerides 98.6 (46.4) 90.6 (39.2) 97.6 (61.0) 94.2 (38.7) 0.62
Total Cholesterol 120.6 (30.7) 124.1 (31.3) 130.2 (32.0) 141.8 (39.8) < 0.0001
LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein cholesterol, Non-HDL = Total Cholesterol - HDL.
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in HIV+ women was entirely explained by the lower
HDL. Unlike HDL, in our study LDL, TG and total-C
were not similar to values in US women–all were mark-
edly lower.
The clinical importance of abnormal lipoprotein levels
lies primarily in the greater risk they confer for develop-
ment of CVD [18,19], and there is growing concern
about premature CVD in both untreated and cART-
treated HIV+ persons [15,16]. However, the lipoprotein
profiles of the HIV-negative RWISA participants are
quite favorable by United States standards, and the
changes associated with HIV-infection may thus not be
clinically significant. Still, subclinical atherosclerosis has
been found to be more common in HIV+ men indepen-
dent of FRS [20] and higher HDL is a powerful protec-
tive factor for cardiovascular disease in women, of
greater importance than it is in men [21,22]. The very
low HDL in untreated HIV+ women and the moderately
higher TG levels may indeed increase CVD risk in Afri-
can women, and further information is needed to deter-
mine whether clinical CVD outcomes will increase with
HIV treatment. Only 15% of HIV-negative and 11% of
HIV+ women had LDL levels above 100 mg/dL, the
most stringent target when treating LDL levels in the
United States.
Some cART regimens are associated with worse lipo-
protein profiles, especially protease inhibitors (PI)
[9,23,24] and stavudine [25,26]. The non-nucleoside
reverse transcriptase inhibitors (NNRTI) have been asso-
ciated with beneficial effects on HDL [24,25]. The
NNRTIs are the most common anchor drugs in cART
regimens in Africa, and stavudine is increasingly
avoided. Thus African women initiating ART may bene-
fit with improved lipoprotein profiles, especially higher
HDL. Follow-up of Africans initiating cART will
improve our understanding of its effects on lipoprotein
levels, potential CVD risk, and the actual rates of CVD
events.
We found that the total body fat did not impact
meaningfully on the HDL and TG values associated
with HIV disease. However, TBF was significantly asso-
ciated with higher LDL, non-HDL and total cholesterol.
The trends in associations of lipid levels with TBF were
similar in the HIV+ and negative women. Thus body
composition was not informative in assessing the impact
of HIV immune suppression.
Limitations of our study include its cross-sectional
design and the absence of information on diet and exer-
cise. Strengths include the relatively large sample size,
the uniformity of specimen and data collection, and the
inclusion of body composition measures.
Conclusion
We found that lower HDL and higher TG were the pri-
mary adverse lipoprotein levels associated with HIV
infection in Rwandan women, while LDL was less
affected. Because HDL is a strong predictor of CVD out-
comes in women, this HIV-associated difference may
carry significant risk of CVD in HIV-infected women.
Longitudinal studies of African women receiving cART
are needed to define these patterns in the presence of
HIV treatment and to ascertain the associated cardiovas-
cular risk.
Acknowledgements
The authors thank the study participants and staff of RWISA, especially Bosco
Ndabarinze. The authors dedicate this paper to the memory of their
colleague Dr. François Ndamage, RWISA Principal Investigator 2007-8.
This study was supported by supplements from the National Institute of
Allergy and Infectious Diseases to the Bronx/Manhattan Women’s
Interagency HIV Study (WIHS), which is funded by the National Institute of
Allergy and Infectious Diseases (UO1-AI-35004). This work was also
supported in part by the AIDS International Training and Research Program
(Fogarty International Center, NIH D43-TW001403) and the Center for AIDS
Research of the Albert Einstein College of Medicine and Montefiore Medical
Center funded by the National Institutes of Health (NIH AI-51519) and by the
National Institute of Diabetes and Digestive and Kidney Disease (DK54615),
and the Chicago WIHS (U01-AI-34993).
Data in this manuscript were presented in part at the XVI International AIDS
Conference, Toronto, Canada; August 13-18, 2006.
Author details
1Montefiore Medical Center, Bronx NY, USA.
2Albert Einstein College of
Medicine, Bronx, NY USA.
3TRAC Plus - Center for Treatment and Research
on AIDS, Malaria, Tuberculosis and other Epidemics, Kigali, Rwanda.
4Data
Solutions LLC, Bronx, NY USA.
5Stroger (Cook County) Hospital and Rush
University, Chicago, Illinois USA.
6New York Medical College, Valhalla, NY
USA.
7SUNY Downstate Medical Center, Division of Cardiovascular Medicine,
Brooklyn NY USA.
8King Faisal Hospital, Kigali, Rwanda.
9Women’s Equity in
Access to Care and Treatment (WE-ACTx) and Kigali Health Institute, Kigali,
Rwanda.
Authors’ contributions
KA obtained funding, designed and implemented the study, participated in
data analysis, and wrote the manuscript; FN assisted in writing early drafts;
DL performed data analysis; MHC helped with study implementation and
reviewed and commented on manuscript; VB performed laboratory analyses,
and reviewed and commented on manuscript; JL provided technical
expertise and reviewed and revised manuscript; EM participated in
manuscript writing and preparation. All authors have read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Table 4 Framingham 10-year risk scores by
HIV-serostatus
HIV
negative
N = 218
HIV-positive
N = 606
P-value
Framingham 10-year risk (FRS) 2.04 (1.7) 1.22 (1.0) < 0.0001
FRS without age component 1.36 (1.2) 1.22 (1.0) 0.15
FRS age-matched (n = 308) 1.57 (1.2) 1.63 (1.6) 0.72
Anastos et al. AIDS Research and Therapy 2010, 7:34
http://www.aidsrestherapy.com/content/7/1/34
Page 5 of 6Received: 6 June 2010 Accepted: 26 August 2010
Published: 26 August 2010
References
1. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, Mantero-
Atienza E, Baum MK: Hypocholesterolemia is associated with immune
dysfunction in early human immunodeficiency virus-1 infection. Am J
Med 1993, 94:515-9.
2. Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C,
Shackleton CH: Increased de novo hepatic lipogenesis in human
immunodeficiency virus infection. J Clin Endocrinol Metab 1993, 76:559-65.
3. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR:
Lipids, lipoproteins, triglyceride clearance, and cytokines in human
immunodeficiency virus infection and the acquired immunodeficiency
syndrome. J Clin Endocrinol Metab 1992, 74:1045-52.
4. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN:
Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J
Med 1989, 86:27-31.
5. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C,
Simonoff M, Brossard G, Barbeau P, Fleury H: Plasma lipids in HIV-infected
patients: a prospective study in 95 patients. Eur J Clin Invest 1994,
24:416-20.
6. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D:
Decreased plasma concentrations of HDL cholesterol in HIV-infected
individuals are associated with immune activation. J Acquir Immune Defic
Syndr 1994, 7:1149-56.
7. Fernandez-Miranda C, Pulido F, Carrillo JL, Larumbe S, Gómez Izquierdo T,
Ortuño B, Rubio R, del Palacio A: Lipoprotein alterations in patients with
HIV infection: relation with cellular and humoral immune markers. Clin
Chim Acta 1998, 274:63-70.
8. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov Dl: HIV
infection and high-density lipoprotein: the effect of the disease vs the
effect of treatment. Metabolism 2006, 55:90-95.
9. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B,
Evans R, Kingsley LA: Impact of HIV infection and HAART on serum lipids
in men. JAMA 2003, 289:2978-82.
10. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C,
Cohen M, Young M, Justman J: Association of Serum Lipid Levels With
HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens. J
Acquir Immune Defic Syndr 2007, 45:34-42.
11. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP,
Wilson PW: Factors associated with low and elevated plasma high
density lipoprotein cholesterol and apolipoprotein A-I levels in the
Framingham Offspring Study. J Lipid Res 1994, 35:871-82.
12. Freedman DS, Bowman BA, Srinivasan SR, Berenson GS, Otvos JD:
Distribution and correlates of high-density lipoprotein subclasses among
children and adolescents. Metabolism 2001, 50:370-376.
13. Fourie CM, Van Rooyen JM, Kruger A, Schutte AE: Lipid abnormalities in a
never-treated HIV-1 subtype C-infected African population. Lipids 2010,
45:73-80.
14. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, Kigozi A,
Borkowf CB, Ndazima V, Brooks JT: Changes in Lipid Profile Over 24
Months Among Adults on First-Line Highly Active Antiretroviral Therapy
in the Home-Based AIDS Care Program in Rural Uganda. J Acquir Immune
Defic Syndr 2008, 47:304-311.
15. The DAD Study Group: Class of antiretroviral drugs and the risk of
myocardial infarction. N Engl J Med 2007, 356:1723-1735.
16. The Strategies for Management of Antiretroviral Therapy (SMART) Study
Group: CD4+ count-guided interruption of antiretroviral treatment. N
Engl J Med 2006, 355:2283-2296.
17. Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis A, Elisaf M,
Tsolas O: Estimation of LDL cholesterol based on the Friedewald formula
and on apo B levels. Clin Biochem 2000, 33:549-555.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final
Report. VIII. Special Considerations for Different Population Groups.
Circulation 2002, 06:3349-3356.
19. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD,
Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein
cholesterol and cardiovascular disease: four prospective American
studies. Circulation 1989, 79:8-15.
20. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, Nasir K,
Grinspoon SK: Increased prevalence of subclinical coronary
atherosclerosis detected by coronary computed tomography
angiography in HIV-infected men. AIDS 2010, 24:243-53.
21. Bittner V: Lipoprotein abnormalities related to women’s health. Am J
Cardiol 2002, 90(8A):77i-84i.
22. Bittner V: Women and coronary heart disease risk factors. J Cardiovasc
Risk 2002, 9:315-22.
23. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC,
Schambelan Ml: Hyperlipidemia and insulin resistance are induced by
protease inhibitors independent of changes in body composition in
patients with HIV infection. J Acquire Immune Defic Syndr 2000, 23:35-43.
24. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA:
Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-
associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a
cohort study. Lancet 1999, 353:2093-9.
25. Van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R,
Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A,
Hall DB, Lange JM, Reiss P: Nevirapine and efavirenz elicit different
changes in lipid profiles in antiretroviral-therapy-naive patients infected
with HIV-1. PLoS Med 2004, 1:e19.
26. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, Sinnott JT:
Lipodystrophy and dyslipidemia among patients taking first-line, World
Health Organization-recommended highly active antiretroviral therapy
regimens in Western India. J Acquir Immune Defic Syndr 2005, 39:199-202.
doi:10.1186/1742-6405-7-34
Cite this article as: Anastos et al.: Lipoprotein levels and cardiovascular
risk in HIV-infected and uninfected Rwandan women. AIDS Research and
Therapy 2010 7:34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Anastos et al. AIDS Research and Therapy 2010, 7:34
http://www.aidsrestherapy.com/content/7/1/34
Page 6 of 6